Protagonist Therapeutics, Inc.
PTGX
$45.80
-$0.48-1.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 448.54% | 221.61% | 223.50% | 215.64% | 38.02% |
| Total Depreciation and Amortization | -12.59% | -3.89% | 0.75% | -2.02% | -1.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.09% | 13.75% | 6.84% | 9.42% | 5.35% |
| Change in Net Operating Assets | -528.41% | 583.15% | 527.95% | -3,239.06% | -151.24% |
| Cash from Operations | 362.19% | 293.80% | 297.19% | 39.59% | 35.05% |
| Capital Expenditure | -122.50% | -61.21% | -65.79% | -58.08% | 23.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -671.37% | -1,418.29% | -260.67% | -139.67% | -141.89% |
| Cash from Investing | -662.86% | -1,455.90% | -262.08% | -140.67% | -142.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -84.55% | -86.60% | -66.18% | 435.91% | 801.25% |
| Repurchase of Common Stock | 21.98% | 21.98% | 22.18% | -1,144.12% | -309.04% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -84.83% | -86.89% | -66.43% | 432.89% | 804.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -246.73% | -227.92% | 4.44% | 53.66% | 2,833.29% |